HCPs: Healthcare professionals; ITT: Intention-to-treat; PP: Per-protocol; UC: Usual care.
• Our initial research suggests that a scoring grid for PRECIS-2 could assist objective scoring of clinical trials on the pragmaticexploratory study design continuum. However, the scoring grid should be further refined in order to ensure more consistent scoring across a range of disease areas and interventions.
• To propose an improvement to the PRECIS-2 scoring method, by providing a scoring grid for retrospective scoring of surgical and pharmaceutical pragmatic clinical trials.
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Development of the scoring grid
• The scoring grid (criteria for each of the 9 domains, for each of the scores 1-5) was defined using guidelines from the PRECIS-2 publication and the example studies provided by the PRECIS-2 authors (Table 1) .
Structured literature review
• A structured literature review was conducted in PubMed (search terms: "pragmatic[title] AND trial[title]") with the publication dates limited to the past 5 years.
• Studies with a single experimental arm compared to usual care, in surgical or pharmaceutical settings were included. Non-patient, behavioural, health service delivery, prognostic, diagnostic and exercise studies, as well as studies investigating a combination of more than one type of intervention, were excluded. • Included studies were assessed according to the PRECIS-2 scoring grid by a primary scorer, followed by an independent assessment by a validation scorer.
Analysis
• A "Study Score" was calculated for each study, based on the sum of scores from the individual domains divided by the number of domains scored.
• Domains that could not be scored due to lack of information were not included in the analysis.
• Average "Study Scores" were calculated for the surgical studies and the pharmaceutical studies.
• In order to analyse the consistency in scoring between the primary scores and the validation scores, the absolute differences were
• Of 341 search results, 6 surgical and 10 pharmaceutical interventions were included.
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• Results from the primary scoring suggest the surgical studies and the pharmaceutical studies to be similar in the degree of pragmatism, with overlapping "Study Score" distributions (mean [SD] Figure 1A and B).
• Domain 6 (Flexibility of experimental intervention (Adherence)) was the most commonly unscored domain due to lack of information. • The most pragmatic domains were domain 3 (Setting, average score 4.83) and domain 9 (Analysis, average score 4.70) for the surgical and pharmaceutical studies respectively. • The results from the analysis of the primary scores were confirmed by the validation scores, which also suggested the surgical and the pharmaceutical studies to be similar, with overlapping "Study Score" distributions (mean [SD] 4.34 [0.44] and 4.21 [0.54] , respectively).
• The AAD was much larger for the pharmaceutical studies (0.7530) than for the surgical studies (0.1875) and in both study types the primary scores were significantly different from the validation scores (paired t-test, p<0.001) ( Figure 1C and D).
calculated and averaged across all the domains and studies (average absolute difference, AAD).
• Paired t-tests were carried out to analyse whether the absolute differences between primary scores and validation scores were significant. Domain and questions to be considered Score 1 (most explanatory) 2 3 4 5 (most pragmatic)
Before scoring the study, it is useful to first define "usual care" and to consider: (A) Which patients is the intervention intended for? (B) What setting is the intervention intended to be used in?
1 Eligibility criteria -Who is selected to participate in the trial?
• What are the inclusion and exclusion criteria?
• Only patients expected to be highly reponsive Flexibility of experimental intervention (Delivery) -How should the intervention be delivered?
• How strict was the trial protocol on delivery of the intervention?
• Rigid prescriptive protocol, with ≥4 of the following items: specific directions for co-intervention; specific directions for managing complications; timing of intervention tightly defined; monitoring of HCPs; restrictions on the numbers and types of co-interventions
• Rigid prescriptive protocol, with ≥3 of the following items: specific directions for co-intervention; specific directions for managing complications; timing of intervention tightly defined; monitoring of HCPs; restrictions on the numbers and types of co-interventions
• Prescriptive protocol, with 1-2 of the following items: specific directions for co-intervention; specific directions for managing complications; timing of intervention tightly defined; monitoring of HCPs; restrictions on the numbers and types of co-interventions
• Protocol has few detailed instructions Follow-up -How closely are patients followed-up?
• How were patients followed-up? • How long were patients followed-up for?
• How frequently were patients followed-up?
• Follow-up only during intervention period • More frequent follow-up visits than UC • More extensive data collection during follow-up visits than UC • Unscheduled follow-up triggered by event also used for data collection
• With 3 of the following items: follow-up only during intervention period; more frequent follow-up than UC; more extensive data collection during follow-up visits than UC; unscheduled follow-up triggered by event also used for data collection
• With 2 of the following items: follow-up beyond intervention period; more frequent follow-up than UC; data collection during follow-up more intensive compared to UC; unscheduled follow-up triggered by event also used for data collection Analysis -To what extent are all data included?
• How was the primary outcome analysed?
• PP analysis excluding non-compliant patients, non-adherent providers and trial sites that recruited below expected volume
• PP analysis with non-compliers excluded • ITT analysis and PP analysis both performed • ITT analysis but excluding patients who withdrew for non-medical reasons
• ITT analysis no matter whether compliance is high or not, or whether patients withdrew for any reason AAD: Average absolute difference.
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• Our analysis did not identify a large difference in the degree of pragmatism between surgical studies and pharmaceutical studies.
• The "Study Score" results should nevertheless be interpreted with care, due to inconsistencies in scoring as well as the following limitations: -Selection bias may have been introduced by our literature review eligibility criteria which excluded combination interventions. The choice of a combination intervention may be part of a pragmatic approach to clinical trial design. -Publication bias is likely to also have been introduced, since only sufficiently credible pragmatic trials would have been accepted by peer reviewers. -The equal weighting of all the domains, and the assignment of criteria along the 1-5 scale, might not necessarily reflect the relative importance of each of the domains for pragmatic clinical trial designs.
• Even though the differences between the primary scores and the secondary scores were significant (p<0.001), these differences might not be meaningful given the low AAD, especially for surgical studies (AAD=0.1875).
• The AAD of the pharmaceutical studies was higher than the AAD of the surgical studies, suggesting that the scoring grid was less well-adapted for scoring of pharmaceutical trials. Other possible reasons for the observed variation include: -Poor reporting: This issue was particularly relevant for domain
